Authorization

Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

a?? ReceivedFDA Orphan Drug and Fast Track designations for novel glioblastoma radiotherapya??a?? Management to host conference call today, Thursday, October 22nd, at 5:00 p.m. ET a??AUSTIN, Texas, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:A PSTV) (the a??Companya??), today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent business highlights.a??Our lead investigational drug, RNLa?? for recurrent glioblastoma, continues to progress toward its first major data readout,a?? said Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics. a??In the third quarter, we advanced RNL successfully to the sixth dosing cohort and we are now administering over 1,000% more radiation to patients in a single treatment than can be delivered with traditional external beam radiation therapy.a??Third Quarter 2020 and Recent Clinical Highlights
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2020    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
30